The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study. - Marković F; Hochmair M; Müser N; Fabikan H; Rodriguez VM; Janzic U; Stjepanović M; Kontić M (Cancers, 2025)